Companies: 10,795·Total market cap: $144.5T
Matinas BioPharma Holdings, Inc.

Matinas BioPharma Holdings, Inc.

MTNBAMEXHealthcare● Active
$0.83
+$0.04(+5.20%)
Market Cap$4609530
P/E Ratio
52W High$3.09
52W Low$0.48
SEC Filings

Matinas BioPharma Holdings, Inc. (MTNB) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001582554 · MTNB · AMEX · as of Jun 9, 2026

Filing snapshot

549
Total Filings
10-Q
Latest Form
2026-05-08
Most Recent
2014
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001582554 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-31
Fiscal Year End
Mar 31, 2026
Accession No.
0001493152-26-014132
Primary Document
form10-k.htm
Source: data.sec.gov · CIK 0001582554 · Accession 0001493152-26-014132

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-08
8-KCurrent Report
8-K
2026-04-03Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-08
View
8-KCurrent Report
8-K
2026-04-03
View
10-KAnnual Report
10-K
2026-03-31
View
8-KCurrent Report
8-K
2026-01-23
View
8-KCurrent Report
8-K
2025-12-12
View
8-KCurrent Report
8-K
2025-11-21
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-14
View
10-QQuarterly Report
10-Q
2025-11-10
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2025-09-25
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2025-08-19
View
8-KCurrent Report
8-K
2025-08-18
View
10-QQuarterly Report
10-Q
2025-08-14
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-08-14
View
8-KCurrent Report
8-K
2025-08-06
View
S-8Employee Stock Plan Registration
S-8
2025-06-23
View
Showing 1–15 of 355 filingsForm 4 / 144 hidden· 549 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001582554  |  Exchange: AMEX · Healthcare

Matinas BioPharma Holdings, Inc. (AMEX: MTNB) has submitted 549 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001582554, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Matinas BioPharma Holdings, Inc.'s most comprehensive regulatory disclosure. The most recent Matinas BioPharma Holdings, Inc. 10-K was filed on 2026-03-31 for fiscal year ending 2026. Historical MTNB 10-K annual reports are available from 2013 through 2026.

Investors researching Matinas BioPharma Holdings, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

MTNB SEC Filings · 8 questions

Matinas BioPharma Holdings, Inc. (MTNB) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 549 filings and access original documents at no cost. Matinas BioPharma Holdings, Inc.'s CIK is 0001582554.

MTNB SEC filingsMatinas BioPharma Holdings, Inc. SEC documentsfind MTNB 10-K